Aptose Biosciences Files 8-K
Ticker: APTOF · Form: 8-K · Filed: Jun 14, 2024 · CIK: 882361
Sentiment: neutral
Topics: disclosure, financials, corporate-update
Related Tickers: APTO
TL;DR
APTO filed an 8-K on 6/14, check for Reg FD and financials.
AI Summary
Aptose Biosciences Inc. filed an 8-K on June 14, 2024, reporting under Regulation FD and including financial statements and exhibits. The company, formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc., is incorporated in Canada and has its principal business address in Toronto.
Why It Matters
This filing provides important updates and disclosures for investors regarding Aptose Biosciences Inc.'s regulatory compliance and financial reporting.
Risk Assessment
Risk Level: low — This is a routine filing for an 8-K, indicating standard corporate disclosures rather than a specific event with immediate high risk.
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- Lorus Therapeutics Inc. (company) — Former Company Name
- Imutec Pharma Inc (company) — Former Company Name
- June 14, 2024 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.
What is the exact name of the registrant?
The exact name of the registrant is Aptose Biosciences Inc.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on June 14, 2024.
What were Aptose Biosciences Inc.'s former company names?
Aptose Biosciences Inc. was formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc.
In which jurisdiction is Aptose Biosciences Inc. incorporated?
Aptose Biosciences Inc. is incorporated in Canada.
Filing Stats: 495 words · 2 min read · ~2 pages · Grade level 9.6 · Accepted 2024-06-14 07:40:15
Filing Documents
- f8k_061324.htm (8-K) — 14KB
- exh_991.htm (EX-99.1) — 14KB
- 0001171843-24-003435.txt ( ) — 228KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_061324_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On June 14, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. 99.1 Press Release dated June 14, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aptose Biosciences Inc. Date: June 14, 2024 By: /s/ William G. Rice, Ph.D. William G. Rice, Ph.D. Chairman, President, and Chief Executive Officer